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Abstract  
Background:  Allergic  rhinitis is  a  prevalent  chronic  respiratory  problem  that  can  impair 
quality of life, sleep and work. The increase in the prevalence of allergic rhinitis among the 
general population appears to have an association with weight. Obese individuals are more 
vulnerable  to  allergy.  Since  obesity  appears  to  be  linked  with  the  occurrence  of  allergic 
rhinitis, it is hypothesized that obesity also has an influence on the severity levels of allergic 
rhinitis. This study was designed to investigate the patterns and severity of allergic rhinitis 
patients, determine the prevalence of obesity in patients with allergic rhinitis, examine the 
association  between  the  severity  of  allergic  rhinitis  and  body  mass  index,  and  develop 
recommendations for further research. 
Methods:  This study involved a descriptive cross-sectional design. Forty five respondents 
aged 8 to 55 years recruited from an outpatient clinic in the Department of Immunology 
Fremantle Hospital from March to August 2007 completed a questionnaire, and had their 
height and weight measured by a trained researcher. Statistical analyses performed included 
chi-square, independent t-test, and logistic regression.  
Results: Increased BMI was associated with more severe conditions (up to six fold) of both 
nasal and non-nasal symptoms of Allergic Rhinitis.  
Conclusions: Weight control should be considered as a potential strategy to improve the 
health status of patients with Allergic Rhinitis, through the control of symptoms and the 
improvement of general health.  
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BACKGROUND 
Allergic  rhinitis  (AR)  is  the  most  common  type  of  rhinitis  caused  by  antigen-antibody 
reaction. It is known to impair quality of life, sleep and work.
1 It is recognized as a global 
health issue, with its prevalence significantly increasing in many countries. Worldwide, it 
affects approximately 25% of the general population, particularly adolescents and adults.
2 In 
Australia,  AR  has  been  identified  by  a  National  Health  Survey  as  a  long  term  medical 
condition and the most prevalent respiratory problem affecting adolescents and young adults.
3, 
4 Although it does not usually lead to severe morbidity and mortality, the impacts of AR on 
health-related quality of life and the cost of treatment have substantial consequences at both 
the individual and community levels.
5 The combination of nasal symptoms of AR (sneezing, 
nasal itching,  rhinorrhea, nasal congestion)  and  non-nasal symptoms (headache and sleep 
disturbance)  can  impair  an  individual’s  physical,  social,  occupational  and  emotional 
functions.
6 Reed et al
5 noted that an impairment of cognitive function, such as an inability to 
concentrate, learn or make decisions, can lead to decreased worker productivity and student 
performance, and hence, the impact of AR is a significant issue.  
 
The  severity  of  AR  is  considered  to  be  an  essential  factor  in  the  management  of  AR, 
regardless of what methods are used to evaluate it.
7 The level of severity determines the 
selection of appropriate treatment for patients with AR. The Allergic Rhinitis and Its Impact 
on Asthma (ARIA) health initiative proposed a new classification of AR based on severity. 
The term ‘intermittent and persistent rhinitis’ was proposed to replace seasonal and perennial 
AR.
8-11 The ARIA also proposed two grades of AR severity: mild and moderate/severe.  
 
To date, few studies have focused on assessment of the severity of AR. Exploring factors that 
influence the severity of this condition would be beneficial for the management of AR. Since 
obesity appears to have a link with the occurrence of AR
12-14, it is hypothesized that obesity 
also has an influence on the severity levels of the condition. This paper presents the findings 
of a study that investigated the severity of AR symptoms, as well as the association between 
AR and body mass index. 
 
METHODS 
Sample 
Participants  of  the  study  were  recruited  from  an  outpatient  clinic  in  the  Department  of 
Immunology  Fremantle  Hospital,  Fremantle,  Western  Australia.  A  convenience  sampling  
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method was used to recruit participants of the study. An inclusion criterion was developed in 
order to determine whether a patient was eligible to be recruited into the study. 
 
Inclusion criteria 
AR patients (perennial type with or without seasonal) in the outpatient clinic who: 
-   visited the outpatient clinic Department of Immunology Fremantle Hospital from March 
to August 2007 (20 weeks) in accordance with the schedule of the Immunology clinic 
(twice weekly); 
-  had  been  diagnosed  by  a  physician  (immunologists)  based  on  the  results  of  allergy 
diagnostic test (at least one type of allergy diagnostic test, either skin prick test or blood 
test (Radioallergosorbent test/RAST) was conducted with positive results);  
-   was aged 8 to 60 years;  
-   presented with or without co-morbidities such as asthma, sinusitis, conjunctivitis, otitis 
media, atopic dermatitis (eczema) and other allergies; and 
-  was  able  to  give  consent  by  themselves  for  those  aged  18  years  and  older  or  by 
parents/guardians for those under 18 years old. 
 
Physicians in the Immunology clinic assisted in the selection of potential participants who 
conformed to the inclusion criteria. After the referral of a potential participant, the researcher 
explained the reason of the study and obtained written informed consent from the potential 
participant or his/her guardian. Forty six patients were eligible for inclusion in the study. 
 
Study design  
The  study  involved  a  descriptive  cross-sectional  design.  A  self-report  questionnaire  was 
completed by each participant, and body weight and height were measured at the hospital by 
the researcher. All questionnaires returned to the researcher within the period from March to 
August 2007 were included (n=45/46 patients). Ethics approval was granted by the Curtin 
University Human Ethics Committee and all participants provided informed consent prior to 
involvement in the study 
 
Instrument (Questionnaire) 
A self-report questionnaire was developed to obtain information about the characteristics of 
AR patients. The questionnaire was divided into five sections as follows:  
    3 
￿  Section one: demographic characteristics including age, sex, level of education, main 
language spoken at home; 
￿  Section two: the history and pattern of AR  
(This  section  aimed  to  obtain  information  about  how  long  the  respondents  have 
suffered from AR since the diagnosis of the condition by a doctor; the period and the 
pattern of the occurrence of the symptoms; the frequency of the symptoms; possible 
triggers  of  the  symptoms;  and  the  impact  of  the  symptoms  on  sleep  and  daily 
activities, which are important in assessing the severity of the condition); 
￿  Section three: the presence of comorbidities: asthma, conjunctivitis, eczema; and the 
family history of asthma, skin allergy and nasal allergy/hay fever; 
￿  Section four: visual analog scales for assessing the severity of AR 
(Visual  analog  scales  (VAS)  have  been  recommended  for  evaluating  the  level  of 
severity of AR symptoms according to the ARIA guidelines.
15 Bousquet et al.
16 also 
find that VAS is a simple quantitative method that can be used for the evaluation of 
AR severity in primary care settings); and 
￿  Section five: the history and pattern of medication 
(This section aimed to obtain information about the pattern of the use of the medical 
treatment, including the use antihistamines, corticosteroids, and immunotherapy. The 
type of medical treatment used can be an indication of the level severity of AR
17; for 
example,  patients  who  take  antihistamines  only  are  more  likely  have  a  milder 
condition of AR than those who take more than one kind of treatment. The use of 
alternative medication such as herbal medicine was also evaluated). 
 
The questionnaire was provided to participants when they visited the outpatient clinic. If the 
participants  were  unable  to  fill  out  the  questionnaire  in  the  clinic,  a  questionnaire  was 
provided to be completed at home with a prepaid envelope. Confidentiality of data collected 
was  maintained  throughout  the  study  and  all  data  were  de-identified  in  all  reports  and 
publications associated with the study.  
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Measurements 
Body Mass Index 
Body weight and height were measured by the researcher at the time respondents visited the 
clinic. Body mass index (BMI) was calculated by dividing weight in kilograms by the square 
of height in meters (kg/m
2). The standard National Institutes of Health definition of obesity
18 
was used in  assessing overweight or obesity among adults. A new international standard 
definition for overweight and obesity published by the International Obesity Task Force
19 was 
used in assessing overweight and obesity among children and adolescents (aged 8-18 years). 
Based on his/her BMI, an individual was classified into normal (BMI ranged from 18.5 to 
24.9 kg/m2), overweight (BMI 25-29.9 kg/m
2), or obese (BMI ≥ 30 kg/m
2). 
 
Level of severity of Allergic Rhinitis  
AR  severity  was  determined  by  adapting  a  standardised  questionnaire  from  the  ARIA 
guidelines
7 and a questionnaire for AR symptoms assessment developed by the Joint Task 
Force on Practice Parameters, representing the American Academy of Allergy, Asthma, and 
Immunology,  the  American  College  of  Allergy,  Asthma,  and  Immunology,  and  the  Joint 
Council of Allergy, Asthma, and Immunology
15. The level of severity was determined based 
on nasal symptoms, non-nasal symptoms, and quality of life related to AR issues including 
sleep disturbance at night, impaired work performance and/or social or recreational activities.  
 
Data analysis 
The  association  between  BMI  and  AR  severity  was  analysed  after  the  respondents  were 
divided into groups based on BMI and the level of severity. The cut-off point of BMI used in 
the analysis was 25 kg/m
2 (e.g. all else classified as overweight or obese).. Respondents were 
categorized into two levels of severity based on the Visual Analog Scales (VAS) for the 
severity of total symptoms, group symptoms (nasal and non-nasal symptoms), and individual 
symptoms, such as sneezing, runny nose, stuffiness, conjunctivitis, and cough. Participants 
scoring three or less on the VAS were categorized as having mild symptoms. Participants 
scoring more than three were categorized as having non-mild symptoms. Data obtained from 
the VAS of nasal and non-nasal symptoms were analysed using inferential statistics with the 
level of significance set at 0.05. In order to compare the mean of the severity level between 
the two groups, an independent sample t-test was utilized. Mann-Whitney U test was used to 
examine possible differences in the severity level of nasal and non-nasal symptoms where a  
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normal distribution was not assumed. Logistic regression was also used in the analysis to 
assess the association between BMI and the severity of AR.  
 
RESULTS 
Sample recruitment  
All  patients  with  AR  who  attended  the  Fremantle  Hospital  Department  of  Immunology 
between March and August 2007 were screened (n=46). Forty five patients completed the 
questionnaire and their height and weight were measured at the hospital. One patient chose to 
fill out the questionnaire at home but did not return it to the researcher. This represented a 
98% response rate from patients with AR in the immunology clinic Fremantle Hospital.  
 
Demographics 
More than half of the respondents were males (n = 26, 53.3%) and the remaining 46.7% were 
females. The mean age of the respondents was 22 years old (SD 15 years). Children and 
adolescents aged 8 to 17 years represented 60% (n = 27) of the sample population, with the 
remaining 40% adults aged 18 to 55 years. 
 
Body Mass Index 
The BMI of all respondents ranged from14.70 to 46.46 kg/m
2 and the mean BMI was 23.32 
kg/m
2 (SD 6.78). The mean BMI of females was 1.99 kg/m
2 higher than males but it was not 
statistically significant (p = 0.116). Compared to children, the mean BMI of adult respondents 
was significantly higher (p < 0.001) with a mean difference of 7.62 kg/m
2 (see Table 1).  
 
Based on his/her BMI, an individual was classified into normal (BMI ranged from 18.5 to 
24.9 kg/m2), overweight (BMI 25-29.9 kg/m
2), or obese (BMI ≥ 30 kg/m
2). The proportion 
of respondents with a BMI < 25 kg/m
2 was 57.8% (n = 26) and the remaining 42.2% (n = 19) 
were those with a BMI ≥ 25 kg/m
2. The proportion of overweight individuals was 26.7%; and 
15.6% of respondents were obese. Due to the small sample size, respondents were commonly 
grouped into two groups, those who were not overweight or obese (BMI <25 kg/m
2) and 
those that were overweight or obese (BMI ≥ 25 kg/m
2). In those classified as overweight or 
obese (BMI ≥ 25 kg/m
2), 57.9% were males and 42.1% were females. The proportion of 
children who were overweight or obese was almost equal to adults (47.4% vs. 52.6%) (see 
Table 2).  
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With a BMI cut-off point of 25 kg/m
2, there was no statistical difference in BMI between 
males and females (p = 0.6) or between children and adults (p = 0.139). 
 
Characteristic of allergic rhinitis 
All respondents presented at the Immunology Clinic with AR symptoms (nasal symptoms, 
e.g. sneezing, runny nose or blocked nose) in the past 12 months. Most of the respondents 
(88.9%)  reported  that  their  nasal  symptoms  were  accompanied  by  itchy  and  watery  eyes 
(rhinoconjunctivitis).  
 
Twenty two per cent of the respondents were newly diagnosed (one year or less) with AR and 
the remainder (78%) had suffered from AR for more than one year. On average, respondents 
had been diagnosed with AR by a doctor when they were 12 years old (12.6 ± SD 10.4). 
 
Perennial AR was the most common type in the study population (88.9%). In respondents 
who  had  the  symptoms  all  year  round,  70%  reported  having  worse  symptoms  during  a 
particular season (perennial AR with seasonal exacerbation), mainly in spring and summer. 
Five out of 45 respondents (11.1%) reported having nasal problems during the same season 
each year (seasonal AR), particularly in September to November (spring season) or in May 
(fall season). In addition, 8.9% of respondents were classified with occupational AR as their 
nasal symptoms mainly occurred during the working day and then disappeared on weekends 
or holidays.  
  
Most of respondents reported having nasal symptoms daily (46.7%) and a few times each 
week (31.1%). The remainder (22.2%) had symptoms less often: weekly (6.7%); monthly 
(8.9%); and a few times each year (6.7%). Using the ARIA guidelines, the respondents can 
be classified into two groups: first, a persistent group - those who have daily symptoms and 
symptoms a few times each week (77.8%); and second, an intermittent group (22.2%) - those 
who have symptoms less often. 
 
Comorbidities 
Of  the  four  common  comorbidities  of  AR  evaluated  in  this  study,  88.9%  of  respondents 
(n=40) reported allergic conjunctivitis symptoms (conjunctivitis symptoms with swelling of 
eyelids), 95.6% (n=42) reported conjunctivitis symptoms (watery and itchy eyes, redness), 
62.2% (n=28) had asthma and 62% of respondents (n = 28) reported sleep disturbances. This  
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last finding was different from the respondents’ answers in the VAS where more details of 
what kinds of sleep problems were provided. Data obtained from the VAS showed that 77.8% 
(n=35) of respondents reported a sleep problem regardless of the severity level of AR. The 
majority of respondents (n = 37, 82%) reported that their nasal problems disturbed their daily 
activities, school, work, leisure, or sport. The impact of this disturbance varied from a little 
(n=16, 43%), to moderate (n=16, 43%) or a lot (n=4, 14%).  
 
Severity levels of allergic rhinitis 
There were two ways of assessing respondents’ severity levels used in the questionnaire. The 
first was by using the VAS, which provide more detailed information of severity levels for 
each nasal and non-nasal symptom. Table 3 shows the summary of the findings of the VAS. 
The second method was by using the following questions: ‘In the past 12 months, how often 
did these symptoms occur?’ (Question.7); ‘In the past 12 months, have these nose problems 
accompanied by sleep disturbance?’ (Question 9); and ‘In the past 12 months, how much has 
this nose problem interfered with your daily activities, and/or school, and/or work, and/or 
leisure, and/or sport?’ (Question.10).  
 
According to the ARIA guidelines, individuals with AR can be classified into four groups: 
mild  intermittent,  mild  persistent,  moderate/severe  intermittent,  and  moderate/severe 
persistent. Based on respondents’ answers from the VAS and Questions. 7, 9 and 10, all 
respondents could be classified into the moderate/severe group. Most of them (77.8%) fell 
into the moderate/severe persistent group and the remaining 22.2% were moderate/severe 
intermittent.  
 
When  respondents  were  asked  to  rate  the  impact  of  both  nasal  and  non-nasal  symptoms 
severity on their general health condition (global assessment, Question 21), they reported that, 
on  average,  they  could  tolerate  the  symptoms  and  were  not  severely  affected  by  the 
symptoms (mean score  3.8 out of 7; where score 1 means severely affected and score 7 
means excellent condition). Although respondents who were overweight or obese (BMI ≥ 25 
kg/m
2) had a higher mean score (4.1) than those with BMI < 25 kg/m
2 (mean score 3.7), the 
mean difference was not statistically significant (p = 0.415).  
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Association between comorbidities of allergic rhinitis and body mass index 
There  were  no  significant  associations  between  BMI  and  physician-diagnosed  asthma, 
eczema and allergic conjunctivitis, however a significant association (p = 0.029) was found 
between BMI and sleep disturbance based on VAS. Table 4 shows that almost all respondents 
with a BMI ≥ 25 kg/m2 (94.7%) reported sleep problems; yet the proportion of those with a 
BMI < 25 kg/m2 who experienced sleep problems was also high (65.4%). Compared to other 
comorbidities, sleep disturbance was more likely to occur in those with a high BMI. The risk 
of experiencing sleep disturbance in respondents who were overweight or obese was 10 times 
higher (OR 9.524, 95% CI 1.088-83.333) than those who were normal weight. 
 
Association between the severity levels of allergic rhinitis and body mass index 
There were two types of analyses used to explore the association between the severity levels 
of AR and BMI: non-parametric (chi-square test) and logistic regression.  
  
Non-parametric analysis 
BMI had a significant association with all AR symptoms (the total of nasal and non-nasal 
symptoms)  and  non-nasal  symptoms  when  analysing  VAS  data  only  (see  Table  5). 
Individuals  with  a  BMI  ≥  25  kg/m
2  had  six  times  greater  risk  of  having  more  severe 
conditions of all AR symptoms (p = 0.024) and 3.5 greater risk of having more severe non-
nasal symptoms (p = 0.047) than those with a BMI < 25 kg/m
2. Table 5 shows the association 
between BMI and the severity level of AR among respondents. 
 
The  severity  levels  of  itchy  nose,  chronic  cough,  ear  symptoms  (e.g.  itching,  popping, 
fullness, and decreased hearing), headache, mental function (e.g. difficulties to concentrate, 
learning impairment), and sleep disturbance seemed to have an association with BMI. Even 
though there was no statistical significance found in this individual symptom analysis, a high 
BMI may lead to a higher risk of more severe conditions of these symptoms particularly in 
non-nasal symptoms as shown in Table 6. For example, individuals with a BMI of 25 kg/m2 
had a 2.7 fold greater risk of experiencing chronic cough, a non-mild symptom.  
 
Logistic regression analysis 
A logistic regression analysis showed that BMI was significantly associated with the severity 
of total symptoms of AR (p = 0.031) with a crude odd ratio (OR) of 6.233 (95% CI 1.186-
32.748).  When  it  was  tested  with  potential  confounders  (age,  sex,  asthma,  or  history  of  
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immunotherapy), none were statistically significant (p > 0.05). Therefore, age, sex, asthma or 
history of immunotherapy were not confounders in the association between BMI and the 
severity of total symptoms of AR. 
 
A second significant result was obtained from a logistic regression analysis for the severity of 
non-nasal symptoms and BMI (p = 0.03, adjusted OR 4.650) where sex was found to be a 
significant  confounder  in  this  association.  Being  a  female  with  a  BMI  ≥  25  kg/m2  was 
associated with a more than four times greater risk of having more severe conditions of non-
nasal  symptoms.  In  contrast,  there  was  no  significant  association  between  BMI  and  the 
severity  of  nasal  symptoms  using  logistic  regression  analysis.  Furthermore,  none  of  the 
potential confounders were statistically significant in this association. 
 
Limitations of the study 
There  are  limitations  to  the  conclusions  that  can  be  drawn  from  this  study.  Firstly,  the 
convenience sampling used in this study was a non-probability approach that may lead to 
sampling  bias.  Secondly,  although  this  study  included  all  but  one  of  the  patients  who 
presented with AR (based on the inclusion criteria) to this major immunology clinic, the 
sample size was relatively small (n=45) thus limiting the general applicability of the findings 
of the study. A small sample size may also lead to some limitations in the application of 
quantitative analysis. Due to the small sample size, no stratified analysis was conducted. 
Thirdly, the measurements in this study were conducted at one point of time (cross sectional) 
and thus, the probability of recall bias was high. Respondents often have trouble answering 
symptoms-related  questions,  particularly  when  completing  visual  analog  scales  (VAS), 
because the frequency and severity of allergic rhinitis symptoms could fluctuate over time. 
Fourthly,  the  severity  of  the  symptoms  was  assessed  based  on  subjective  measurements. 
Therefore, the responses given by the respondents may not consistent to represent the real 
condition of the respondents. 
 
It should be noted that the immunology clinic from which the sample were recruited is in one 
of the major hospitals in WA and all but one of the eligible patients who attended the clinic 
participated  in  the  study.  While  this  study  had  some  limitations,  the  findings  suggest 
validation by further research is worthwhile.  
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DISCUSSION 
The aim of this study was to investigate the association between AR and body mass index. To 
achieve this, finding the characteristics of individuals with AR, including the demographic 
factors, comorbidities and the severity of the condition, and observing obesity-related issues 
among respondents were considered to be essential.  
 
Characteristics of patients with allergic rhinitis 
The first characteristic of interest in patients with AR was age. This study found that the 
majority of patients with AR in the Immunology Clinic Fremantle Hospital were children (n 
= 27, 60%). This is in agreement with the findings of the National Health Survey where the 
prevalence of AR was  high in  children and adolescents.
3,  4  Furthermore, this study  also 
observed that, on average, the symptoms of AR started at a young age, where the mean age of 
being first-diagnosed with AR was 12  years old (± 10  years). Huurre  et al
20 argued that 
typically, AR symptoms begin during childhood and continue into adulthood. Thus, a high 
prevalence of AR in children and adolescents can be attributed to the natural history of AR. A 
high proportion of children in this study may also be attributed to parents’ decisions to take 
their children to the specialised clinic for better treatment of AR symptoms. AR is known to 
have an impact not only on children’s daily activities, social and emotional functions, and 
their performance at school (inability to learn and concentrate)
6, 21, but it may also affect 
parents productivity
22. 
 
The  second  characteristic  of  interest  was  gender.  As  reported  by  several  epidemiological 
studies, the prevalence of AR was slightly higher in males than females.
11, 20, 23 In this study, 
the  proportion  of  male  and  female  respondents  was  almost  equal  (53%  vs.  47%).  This 
suggests that females may have the same risk as males in developing AR. 
 
Another point of interest was comorbidities. All respondents reported that they had at least 
one  comorbid  condition.  Conjunctivitis  was  the  most  common  comorbidity  among 
respondents (n = 42, 96%). This finding is in agreement with other studies where rhinitis 
often coexists with conjunctivitis.
7, 24, 25 That is why rhinoconjunctivitis has been frequently 
used as a dependent variable in surveys of AR or atopic diseases, such as the ISAAC and the 
European Community Respiratory Health Survey (ECRHS), instead of using rhinitis only.
7, 24 
Although the majority of respondents in this study had eye symptoms, only one third of them 
reported that they had been diagnosed with allergic conjunctivitis. There are two reasons why  
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the  prevalence  of  allergic  conjunctivitis  is  often  underestimated.  Firstly,  conjunctivitis 
symptoms with/without allergy, such as red and/or itchy eyes, have been considered to be less 
important than other symptoms by patients with rhinitis and/or asthma and it is more likely 
that patients do not report this problem spontaneously.
7 Secondly, allergic conjunctivitis can 
present  with  a  variety  of  signs,  symptoms,  and  responses  to  treatment.  Thus  an  accurate 
history of the symptoms presented and a thorough eye examination are required to avoid 
misdiagnosis.
26 
 
This study also shows that sleep disturbance was a major issue in patients with AR. Almost 
all respondents who were overweight or obese (95%) reported sleep problems. It has been 
known  that  a  high  body  mass  index  is  strongly  associated  with  sleep  disturbance.
27-30  
However, this study showed that not only those who have a high BMI experienced sleep 
disturbance,  as  it  was  also  prevalent  in  those  with  normal  weight.  Almost  two  third  of 
respondents (65%) with normal weight reported the same problems. This finding suggests 
that sleep disturbance is an important issue in individuals with AR, regardless of their BMI. 
 
Compared to those who were normal weight, respondents who were overweight or obese had 
a 10 fold greater risk of experiencing sleep disturbance. There were two factors why those 
with AR and also a high BMI were more susceptible to experiencing sleep problems. Firstly, 
a high BMI has a significant impact on sleep and secondly, as illustrated above, AR itself has 
a direct impact on sleep.
21, 31-33 The combination of these two factors can lead to a more 
severe sleep disturbances among individuals with AR and also a high BMI. Milder sleep 
problems were more likely to occur in those with a normal BMI. However, this study cannot 
explain  which  factor,  obesity  or  AR,  had  the dominant  role  in the  development  of  sleep 
disturbance. 
 
Obesity in patients with allergic rhinitis 
Obesity  was  a  significant  issue  among  respondents  in  this  study.  The  prevalence  of 
overweight or obese (BMI ≥ 25 kg/m
2) was high in both children and adults regardless of sex. 
One  in  three  children  was  overweight  or  obese  (33%).  One  in  two  adults  (55.7%)  was 
overweight or obese; and at least, one in four adults (28%) was classified as obese (BMI ≥ 30 
kg/m
2).  The  prevalence  of  overweight  or  obese  in  adults  observed  in  the  latest  National 
Health Survey  (1994-1995) was similar to this study.  In the National Health Survey, the 
prevalence of overweight or obese observed was, on average, 53.5% (62% of males, 45% of  
    12 
females). This finding is also in agreement with Seidell and Flegall
34 where the prevalence of 
overweight or obese appeared to have a link with age. As age increased, the prevalence of 
overweight or obesity also increased. 
 
High childhood obesity was also observed in this study. The prevalence of obesity among 
children in this study (7.4%) is similar to the findings of a cross-sectional survey of 2184 
children  in  Victoria,  Australia  where  the  prevalence  of  obesity  was  7.6  (±  0.6%).
35    It 
confirms that high childhood obesity is evident at the population level and thus, is one of the 
major public health problems in Australia.  
 
Obesity and the severity of allergic rhinitis  
Based on the ARIA classification, the severity  level of all respondents in this study was 
moderate/severe,  where  most  of  them  (78%)  presented  with  persistent  rhinitis  and  the 
remainder (22%) with intermittent rhinitis. This finding is in agreement with the findings of a 
cross-sectional study in France
9 where the majority of AR patients who visited specialist 
clinics had severe symptoms; and persistent rhinitis was more prevalent than intermittent 
rhinitis  in  the  study  population.  Bousquet  et  al
9  argued  that  most  patients  with  AR  who 
consulted with a specialist present with severe and/or persistent symptoms. 
 
This study found that there was a significant association between the severity of AR and BMI. 
Respondents who were  overweight or obese had a six times greater risk of having more 
severe conditions of all AR symptoms (p = 0.024) than those with normal weight (BMI < 25 
kg/m
2), where age, gender, asthma or immunotherapy was controlled for. In the analysis of 
symptom groups (logistic regression), a significant result was found in non-nasal symptoms 
only. Respondents who were overweight or obese had a 3.5 times greater risk of having more 
severe non-nasal symptoms, such as ocular symptoms, cough, ear symptoms and headache. 
The risk increased when gender was put into the model (adjusted OR 4.650, 95% CI 1.156-
18.700, p=0.03). Being an overweight or obese female was associated with a more than four 
times greater risk of having more severe non-nasal symptoms. In contrast, the association 
between BMI and the severity of nasal symptoms was not statistically significant (crude OR 
1.382, 95% CI 0.340-5.617, p=0.62).  
 
In the analysis of individual symptoms, it was evident that, compared to those with normal 
BMI, respondents who were overweight or obese were more likely to experience more severe  
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conditions of the following symptoms: itchy nose (OR 1.589, 95% CI 0.459-5.498); cough 
(OR 2.738, 95% CI 0.565-13.267); ear symptoms (OR 1.944, 95% CI 0.528-7.166); headache 
(OR 1.440, 95% CI 0.435-4.771); mental function (OR 1.974, 95% CI 0.562-6.939); and 
sleep disturbance (OR 1.179, 95% CI 0.357-3.887). Although the association between BMI 
and  these  individual  symptoms  was  not  statistically  significant  (p>0.05),  these  findings 
suggest that a high BMI may play an important role in the severity of individual symptoms of 
AR.  
 
Studies  assessing  the  association  between  AR  and  BMI  have  conflicting  results.  Several 
epidemiological  studies  showed  a  positive  association  between  AR  and  high  BMI,
14,  36-38  
whereas  other  studies  reported  that  there  was  no  association  between  AR  and  BMI 
39,40. 
While  it  is  uncertain  if  BMI  has  an  important  role  in  the  occurrence  of  AR,  this  study 
suggests  that  BMI  was  significantly  associated  with  the  severity  of  AR.  Furthermore,  it 
appears that obesity may be a potentially modifiable risk factor for AR, particularly relating 
to the severity of AR symptoms. Promoting healthy weight to patients with AR may have a 
favourable impact on controlling the severity of AR symptoms. However, further studies may 
need to be designed to investigate this issue further. 
 
CONCLUSIONS 
Weight control should be considered as a potential strategy to improve the health status of 
patients  with  AR.  This  strategy  could  be  applied  together  with  the  treatment  of  AR 
recommended  by  the  ARIA,  which  includes  the  combination  of  allergen  avoidance, 
pharmacotherapy  and  immunotherapy.  Healthy  weight  may  play  an  important  role  in 
preventing individuals with AR from experiencing more severe AR symptoms as well as 
reducing the risk of experiencing sleep disturbance. The possibility that AR may lead to 
obesity should also be considered. For example, poor sleep associated with AR could lead to 
reduced energy, increased stress and stress-related eating, and/or less inclination to exercise, 
resulting in excessive weight gain. Incorporating weight control in the management of AR is 
useful not only for reducing the severity of AR symptoms, but also for improving general 
health, including reducing the risk of obesity-related diseases, such as cardiovascular disease, 
diabetes, hypertension and stroke.  
 
Within  the  limitations  of  the  current  study,  the  research  provides  insight  into  the 
characteristics of patients with AR and the association between BMI and the severity of AR.  
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These will assist in understanding and improving the management of AR. The findings of this 
study also have implications for future research. These relate to the extension of the focus of 
the  research,  replication  of  the  methods  used,  the  selection  of  target  population  and  the 
duration of the research. Further research focusing on investigating potential factors that can 
contribute  to  the  severity  of  AR  is  recommended.  Furthermore,  since  AR  is  a  chronic 
condition, the development of a long-term strategy as well as short-term strategy to manage 
the condition is important.  
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List of abbreviations used  
  ARIA    Allergic Rhinitis and Its Impact on Asthma 
An  international  health  initiative  on  allergic  rhinitis  which  aims  to 
educate and implement evidence-based management of allergic rhinitis 
in conjunction with asthma. 
 
ISAAC  The International Study of Asthma and Allergy in Childhood 
International  collaborative research projects which focus on  asthma, 
allergic rhinitis and eczema by promoting a standardized methodology. 
 
BMI  Body Mass Index 
A simple index of weight-for-height (kg/m
2). It is commonly used to 
define  obesity.  An  individual  is  considered  obese  if  his/her  BMI  is 
greater than 30 kg/m
2. 
 
VAS  Visual Analog Scales 
A tool used to help a person rate the intensity of certain sensations and 
feelings, such as severity of nasal symptoms. The visual analog scale 
for severity of nasal symptoms is a straight line with one end meaning 
no  problem  and  the  other  end  meaning  the  most  severe  condition 
imaginable.  A  patient  marks  a  point  on  the  line  that  matches  the 
amount of severity of nasal symptoms he or she feels. 
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TABLES  
Table 1  The Body Mass Index of respondents 
By sex    By age group   
All 
Males  Females 
  Children 
(< 18 year old) 
Adults 
(≥ 18 year old) 
Mean  23.3236  22.3946  24.3852    20.2730  27.8994 
Median  22.1600  20.0800  22.6200    19.5400  26.8050 
Std. Deviation  6.7832  7.5865  5.7288    4.5579  7.0969 
Minimum  14.70  15.09  14.70    14.70  19.22 
Maximum  46.46  46.46  34.25    31.23  46.46 
Mean difference 
(p value) 
  1.9906 
(p = 0.116)* 
  7.6265 
(p < 0.001)** 
* Mann-Whitney U test 
** T-test 
 
 
Table 2  Prevalence  of  overweight  and  obesity  in  patients  with  allergic  rhinitis  in 
Immunology Clinic Fremantle Hospital (March-August 2007) 
 
Prevalence   
Normal weight 
n (%) 
Overweight 
n (%) 
Obese 
n (%) 
All   26 (57)  12 (26.7)  7 (15.6) 
By sex       
Males  13 (54.2)  7 (29.2)  4 (16.7) 
Females  13 (61.9)  5 (23.8)  3 (14.3) 
By age group       
Children  18 (66.7)  7 (25.9)  2 (7.4) 
Adults  8 (44.4)  5 (27.8)  5 (27.8) 
 
 
 
 
 
 
  
    19 
 
 
 
 
 
Table 3   Respondents’  severity  levels  of  allergic  rhinitis  based  on  7-point  visual  analog 
scales (VAS) 
  Mean  SD 
All symptoms  3.4  1.0 
     
Nasal symptoms  4.01  1.19 
Sneezing   3.83  1.47 
Runny nose  4.18  1.48 
Congestion (stuffiness)  4.76  1.56 
Itchy nose   3.81  1.85 
Postnasal drip   3.49  1.87 
     
Non-nasal symptoms  3.04  1.09 
Eye symptoms  3.49  1.52 
Throat symptoms  3.14  1.56 
Chronic cough  2.43  1.50 
Ear symptoms  2.86  1.67 
Headache   2.97  1.67 
Mental function  2.73  1.74 
Sleep disturbance  3.63  1.94 
 
 
 
Table. 4  Cross-tabulation between BMI and sleep disturbance 
   
BMI  Total    
  
  
  
< 25 kg/m2  ≥ 25 kg/m2  normal 
Sleep disturbance  yes  Count  17  18  35 
      % within BMI_cut25  65.4%  94.7%  77.8% 
             
   no  Count  9  1  10 
      % within BMI_cut25  34.6%  5.3%  22.2% 
             
Total  Count  26  19  45 
   % within BMI_cut25  100.0%  100.0%  100.0% 
Fisher’s exact test: p = 0.029 
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Table 5  Non-parametric analysis between BMI and the groups of severity of allergic 
rhinitis symptoms 
95% CI for OR 
Severity 
Chi-square 
(p-value) 
OR 
Lower  Upper  
All symptoms  0.020 
0.024* 
6.233  1.186  32.748 
Nasal symptoms  0.651 
0.736* 
1.382  0.340  5.617 
Non-nasal symptoms  0.047  3.467  0.994  12.088 
* Fisher’s exact test 
 
Table 6  Non-parametric analysis between BMI and the severity levels of each symptoms of 
allergic rhinitis  
95% CI for OR 
Symptoms 
Chi-square 
(p-value) 
OR 
Lower  Upper  
Nasal symptoms  Sneezing  0.912  1.071  0.316  3.636 
  Runny nose  0.954  0.963  0.269  3.451 
  Stuffiness  0.623 
0.704* 
0.682  0.147  3.160 
  Itchy  0.463  1.589  0.459  5.498 
  Postnasal drip  0.862  0.900  0.275  2.941 
Non-nasal symptoms  Eye  0.227  0.476  0.142  1.598 
  Throat  0.532  0.681  0.203  2.282 
  Cough  0.200 
0.253* 
2.738  0.565  13.267 
  Ear   0.314  1.944  0.528  7.166 
  Head  0.550  1.440  0.435  4.771 
  Mental function  0.286  1.974  0.562  6.939 
  Sleep   0.787  1.179  0.357  3.887 
* Fisher’s exact test 
 
 